vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Marygold Companies, Inc. (MGLD). Click either name above to swap in a different company.
Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $3.9M, roughly 1.9× Citius Pharmaceuticals, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -238.2%, a 230.6% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.
CTXR vs MGLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $7.6M |
| Net Profit | $-9.4M | $-576.0K |
| Gross Margin | 80.0% | 74.0% |
| Operating Margin | -228.7% | -8.3% |
| Net Margin | -238.2% | -7.5% |
| Revenue YoY | — | -4.5% |
| Net Profit YoY | 8.6% | 67.0% |
| EPS (diluted) | $-0.38 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | $7.6M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $7.2M | ||
| Q1 25 | — | $7.0M | ||
| Q4 24 | — | $8.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $7.9M |
| Q4 25 | $-9.4M | $-576.0K | ||
| Q3 25 | — | $-356.0K | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-1.0M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-1.6M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-529.0K |
| Q4 25 | 80.0% | 74.0% | ||
| Q3 25 | — | 77.0% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 75.0% | ||
| Q4 24 | — | 74.1% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 72.5% | ||
| Q1 24 | — | 70.5% |
| Q4 25 | -228.7% | -8.3% | ||
| Q3 25 | — | -18.2% | ||
| Q2 25 | — | -16.5% | ||
| Q1 25 | — | -21.4% | ||
| Q4 24 | — | -22.8% | ||
| Q3 24 | — | -27.4% | ||
| Q2 24 | — | -33.3% | ||
| Q1 24 | — | -18.7% |
| Q4 25 | -238.2% | -7.5% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | -20.4% | ||
| Q1 25 | — | -14.4% | ||
| Q4 24 | — | -21.8% | ||
| Q3 24 | — | -20.1% | ||
| Q2 24 | — | -22.5% | ||
| Q1 24 | — | -6.7% |
| Q4 25 | $-0.38 | $-0.01 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $11.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $22.7M |
| Total Assets | $140.4M | $27.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | $11.6M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | — | $12.8M | ||
| Q1 25 | — | $15.6M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | — | $17.5M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $16.1M |
| Q4 25 | $80.0M | $22.7M | ||
| Q3 25 | — | $22.9M | ||
| Q2 25 | — | $23.0M | ||
| Q1 25 | — | $24.3M | ||
| Q4 24 | — | $23.4M | ||
| Q3 24 | — | $25.5M | ||
| Q2 24 | — | $26.6M | ||
| Q1 24 | — | $28.4M |
| Q4 25 | $140.4M | $27.8M | ||
| Q3 25 | — | $28.4M | ||
| Q2 25 | — | $30.4M | ||
| Q1 25 | — | $33.5M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | $35.9M | ||
| Q2 24 | — | $32.9M | ||
| Q1 24 | — | $33.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $-908.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | $-908.0K | ||
| Q3 25 | — | $-533.0K | ||
| Q2 25 | — | $-3.3M | ||
| Q1 25 | — | $-1.2M | ||
| Q4 24 | — | $-770.0K | ||
| Q3 24 | — | $-893.0K | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-658.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-562.0K | ||
| Q2 25 | — | $-3.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-776.0K | ||
| Q3 24 | — | $-940.0K | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -8.1% | ||
| Q2 25 | — | -46.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | — | -11.9% | ||
| Q2 24 | — | -23.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTXR
Segment breakdown not available.
MGLD
| Fund Management Related Party | $4.6M | 60% |
| Food Products | $1.7M | 22% |
| Beauty Products | $1.2M | 15% |
| Other | $268.0K | 4% |
